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Cost effectiveness analysis of different approaches of
screening for familial hypercholesterolaemia
Dalya Marks, David Wonderling, Margaret Thorogood, Helen Lambert, Steve E Humphries,
H Andrew W Neil
Abstract
Objectives To assess the cost effectiveness of
strategies to screen for and treat familial
hypercholesterolaemia.
Design Cost effectiveness analysis. A care pathway for
each patient was delineated and the associated
probabilities, benefits, and costs were calculated.
Participants Simulated population aged 16›54 years
in England and Wales.
Interventions Identification and treatment of patients
with familial hypercholesterolaemia by universal
screening, opportunistic screening in primary care,
screening of people admitted to hospital with
premature myocardial infarction, or tracing family
members of affected patients.
Main outcome measure Cost effectiveness calculated
as cost per life year gained (extension of life
expectancy resulting from intervention) including
estimated costs of screening and treatment.
Results Tracing of family members was the most cost
effective strategy (£3097 (&5066, $4479) per life year
gained) as 2.6 individuals need to be screened to
identify one case at a cost of £133 per case detected. If
the genetic mutation was known within the family
then the cost per life year gained (£4914) was only
slightly increased by genetic confirmation of the
diagnosis. Universal population screening was least
cost effective (£13 029 per life year gained) as 1365
individuals need to be screened at a cost of £9754 per
case detected. For each strategy it was more cost
effective to screen younger people and women.
Targeted strategies were more expensive per person
screened, but the cost per case detected was lower.
Population screening of 16 year olds only was as cost
effective as family tracing (£2777 with a clinical
confirmation).
Conclusions Screening family members of people
with familial hypercholesterolaemia is the most cost
effective option for detecting cases across the whole
population.
Introduction
Familial hypercholesterolaemia is an autosomal domi›
nant condition caused mainly by mutations of the low
density lipoprotein receptor gene which result in
substantially raised serum cholesterol concentrations.1
Men with this condition have over a 50% risk of coron›
ary heart disease by the age of 50 years. For women the
risk is at least 30% at 60 years.2 3 About 110 000 people
in the United Kingdom are thought to be affected, and
at least 75% of them are undiagnosed.4 Treatment with
hydroxymethyl glutaryl coenzyme A (HMG›CoA)
reductase inhibitors (statins) is effective5 6 and delays or
prevents the onset of coronary heart disease.7–10 Effec›
tive primary prevention, however, requires early
diagnosis.
A diagnosis of familial hypercholesterolaemia is
made on the basis of the plasma total and low density
lipoprotein cholesterol concentrations combined with
either a clinical examination and family history11 or a
genetic test. When a mutation is known within a family
an unequivocal diagnosis can be made by DNA testing
at any age.12 A mutation is detected in only half of clini›
cally identified cases, probably because of technical
insensitivity, clinical misdiagnosis, or causes of familial
hypercholesterolaemia not related to the low density
lipoprotein gene.13
One report on the cost effectiveness of screening
for familial hypercholesterolaemia was published in
199314 and updated in 1997.15 This reported US data
and did not present costs and effectiveness separately
so it is not possible to adapt the findings to the United
Kingdom. We carried out a modelling exercise to
determine the costs and benefits of different screening
strategies in the United Kingdom.
Methods
We identified potential screening strategies in a
systematic literature review16: universal population
screening; opportunistic screening of patients consult›
ing for unrelated reasons in primary care; opportunis›
tic screening of patients admitted to hospital with
premature myocardial infarction; and systematic
screening of first degree relatives of people with
diagnosed familial hypercholesterolaemia. We added
to these the option of screening all young people aged
16 years. With the exception of screening 16 year olds,
outcomes were modelled for each sex within 10 year
age bands from 16 to 54 years because there are no
clinical endpoint data to support the effectiveness of
statin treatment at later ages.
London School of
Hygiene and
Tropical Medicine,
London
WC1E 7HT
Dalya Marks
research fellow
David Wonderling
research fellow
Margaret
Thorogood
reader in public
health and
preventative medicine
Department of
Social Medicine,
University of
Bristol, Bristol
BS8 2PR
Helen Lambert
senior lecturer
Centre for
Cardiovascular
Genetics, University
College London
Medical School,
London WC1E 6JF
Steve E Humphries
professor
Oxford Centre for
Diabetes,
Endocrinology and
Metabolism,
Radcliffe Infirmary,
Oxford OX2 6HE
H Andrew W Neil
honorary consultant
physician
Correspondence to:
M Thorogood
Margaret.Thorogood@
lshtm.ac.uk
bmj.com 2002;324:1303
page 1 of 6BMJ VOLUME 324 1 JUNE 2002 bmj.com
We developed a hypothetical care pathway (figure).
In the universal and opportunistic strategies, people
with a non›fasting total cholesterol concentration
above the population 95th centile are invited for a fast›
ing blood test. Those with a confirmed fasting total
cholesterol concentration above 7.5 mmol/l and low
density lipoprotein cholesterol above 4.9 mmol/l are
referred for diagnostic confirmation by clinical
examination with a lipid clinic consultant or by genetic
testing on blood or buccal cells. For the family tracing
strategy, a lipid clinic nurse approaches existing
patients, collects family histories, and asks permission
to approach relatives.17 For each strategy we used a
combination of decision analysis and life table analysis
to estimate life years gained per case diagnosed as a
result of screening and subsequent treatment with stat›
ins; number needed to screen, defined as the number
of people who must be invited for screening for one
case to be identified; cost of screening per case
diagnosed; and cost effectiveness in terms of the cost
per life year gained.
We calculated the life years gained that were attrib›
utable to the use of statins by patients with familial
hypercholesterolaemia as the life expectancy (expected
age at death) with statin treatment minus the life
expectancy in the absence of treatment for each age
and sex group. We constructed life expectancy tables
using mortality data from a UK cohort of 1185 patients
with heterozygous familial hypercholesterolaemia who
have been followed prospectively since 1980. From
1992 treatment was mostly with statins; before 1992
treatment was with bile acid sequestrants.5 This cohort
study was the only published report of the effect of
statins on mortality in familial hyperlipidaemia that we
identified. We used population mortality in the life
tables for ages 60 years and over because the cohort in
this age range was small.
We calculated the number needed to screen and
the screening cost per person invited using a decision
analytic model. Unit cost data (including laboratory
costs, staff time, letters, and overheads) and probabili›
ties (including attendance rates and prevalence of
familial hypercholesterolaemia) were taken from
published sources where available (table 1).
We calculated screening cost per case diagnosed as
the screening cost per person invited multiplied by the
number needed to screen. We calculated the cost per
life year gained (C/LYG) as the screening cost per
patient diagnosed (ScreenCost) plus the additional
drug costs arising from the new diagnoses
(StatinCostScreen–StatinCostNoScreen) plus the cost savings
due to reduced incidence of coronary events
(EventCostScreen–EventCostNoScreen) divided by the life
years gained (LYScreen–LYNoScreen): C/LYG=(ScreenCost+
(StatinCostScreen–StatinCostNoScreen)+(EventCostScreen–
EventCostNoScreen))/(LYScreen–LYNoScreen).
We estimated the annual cost of treatment to be
£411 (&672, $594) with a treatment regimen of statin
therapy (70% simvastatin 40 mg daily and 30%
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5&6
Probability
Attends for first blood test
Blood cholesterol
concentration above cut off
Attends for second blood test
Blood cholesterol
concentration above cut off23
Familial hypercholesterolaemia*16
*Data taken from Marks et al16 and depend on prevalence of familial hypercholesterolaemia
and probability of high cholesterol concentration in target population. 
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0.935
0.038
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0.60017
0.29019
0.90022
0.935
0.160
Family
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0.95018
0.49020
0.90022
0.935
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Exit
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Exit
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Exit
screening
Exit
screening
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Decision tree used in the modelling
Table 1 Costs and probabilities assigned to each screening strategy for familial hypercholesterolaemia
Cost code* Description Price Source
Stage 1,2,3,4 Invitation or results letter plus reminders £0.50 Estimated cost of sending average of 1.5 letters
Stage 2›3 10 minute nurse appointment £4.50 Netten et al24—£27 per hour of patient contact time (includes
salary, on costs, overheads, capital overheads, training, and
non›contact time)
Stage 2 Cholesterol test £3.77 Total cholesterol (Diabetes Research Laboratory, Oxford)
Stage 4 30 minute nurse appointment £13.50 Netten et al24
Stage 4 Lipid profile £11.82 £3.77 for total cholesterol, £3.94 for high density lipoprotein
cholesterol, £4.11 for triglycerides (Diabetes Research Laboratory,
Oxford)
Stage 5›6 Outpatient appointment with consultant at lipid clinic £67.00 Netten et al24
Stage 5›6 Genetic test (proband) £1000 Clinical Molecular Genetics Laboratory, Institute of Child Health
Stage 5›6 Genetic test (family member) £185 Clinical Molecular Genetics Laboratory, Institute of Child Health
*See figure.
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atorvastatin 20 mg daily, based on data from a special›
ist lipid clinic) and an annual general practitioner
appointment until the age of 60 years. We calculated
drug costs after allowing for an 18% rate of
non›adherence to treatment. The cost of a coronary
event was taken as £1544.25 We calculated the lifetime
cost of drug and event treatment using the life tables.
We discounted life expectancy and life years gained
at 1% and costs at 6% in accordance with Treasury and
Department of Health guidelines.26 We carried out sen›
sitivity analyses by altering parameters in five areas to
check the robustness of the model. Marks et al give fur›
ther details of the modelling procedures and
assumptions.16 The full HTA report can be found at
www.hta.nhsweb.nhs.uk/fullmono/mon429.pdf.
Results
Increase in life expectancy
Table 2 shows the change in life expectancy by sex after
diagnosis and treatment. The gain in life years was
highest when treatment was started earliest (7.0 years
in men and 9.1 years in women aged 16›24 years) and
decreased with increasing age (0.3 and 3.4 years at age
45›54 years).
Number needed to screen
The number needed to be invited for screening to result
in the identification of one person with familial hyperc›
holesterolaemia is determined by the prevalence of
familial hypercholesterolaemia, the attendance rate in
the care pathway, and by whether a clinical or genetic
confirmation of diagnosis is made (table 3). A genetic
confirmation of diagnosis requires greater numbers
because currently a mutation is detected in only half of
clinically diagnosed cases.13 The number varied from
2292 people in the general population (confirmed by
genetic screening) to 2.6 people in first degree relatives
of identified cases (with clinical confirmation).
Cost per case detected
The cost per case detected is the number needed to
screen multiplied by the cost per person invited. More
targeted strategies are more expensive but fewer
people need be invited to find one case. Costs per case
detected ranged from £133 for a clinically diagnosed
relative (family tracing) to £9645 in a population wide
strategy (clinically confirmed) (table 3).
Cost effectiveness ratios
Table 4 shows cost effectiveness of the screening
strategies with clinical or genetic confirmation of diag›
nosis together with undiscounted rates and results for
cost and effectiveness data discounted at 3% for
comparison. The earlier a diagnosis of familial hyper›
cholesterolaemia is made the more cost effective the
screening strategy becomes (£2777 per life year gained
for 16 year olds). In addition, identification of relatives
is the most cost effective for all age groups (£3097 to
£4914 per life year gained).
Screening women was more cost effective than
screening men because women gained more life years
Table 2 Life expectancy (expected age at death) of people with familial hypercholesterolaemia with and without treatment
Age at start of treatment
(years)
Undiscounted Discounted at 1%
Untreated Treated Increment Untreated Treated Increment
Men
16 65.64 72.76 7.11 53.37 58.18 4.82
16›24 66.09 73.05 6.97 55.11 60.13 5.02
25›34 70.72 74.42 3.70 62.08 64.87 2.79
35›44 75.05 75.62 0.57 68.63 69.06 0.43
45›54 77.92 78.18 0.26 73.63 73.85 0.21
Women
16 71.87 81.04 9.17 57.42 63.03 5.60
16›24 72.01 81.14 9.13 59.19 65.12 5.92
25›34 73.35 81.51 8.16 63.86 69.48 5.62
35›44 74.51 81.84 7.33 67.91 73.42 5.51
45›54 79.44 82.85 3.41 74.56 77.31 2.75
Table 3 Comparison of overall cost per life year gained of different screening strategies
using clinical or genetic confirmation of diagnosis
Strategy
Main results Results with alternative discount rates
Baseline discount rates
(effectiveness 1%; costs 6%)
Undiscounted
effectiveness
Costs and effectiveness
discounted at 3%
Clinical
Universal (16 year olds) £2777 £1798 £7 244
Universal £13 029 £10 269 £21 289
Opportunistic (GP)* £11 310 £8909 £18 578
Opportunistic (MI)† £9281 £7513 £15 738
Family tracing £3097 £2420 £6 084
Genetic
Universal (16 year olds) £14 842 £9610 £33 882
Universal £78 060 £61 661 £120 841
Opportunistic (GP)* £70 009 £55 283 £108 578
Opportunistic (MI)† £21 106 £17 116 £32 833
Family tracing £4914‡ £3856 £8 865
*Patients attending general practitioner.
†Patients hospitalised for myocardial infarction.
‡Including cost of finding mutation in proband.
Table 4 Comparison of overall cost per life year gained of different screening strategies
using clinical or genetic confirmation of diagnosis
Strategy
Main results Results with alternative discount rates
Baseline discount rates
(effectiveness 1%; costs 6%)
Undiscounted
effectiveness
Costs and effectiveness
discounted at 3%
Clinical
Universal (16 year olds) £2777 £1798 £7 244
Universal £13 029 £10 269 £21 289
Opportunistic (GP)* £11 310 £8909 £18 578
Opportunistic (MI)† £9281 £7513 £15 738
Family tracing £3097 £2420 £6 084
Genetic
Universal (16 year olds) £14 842 £9610 £33 882
Universal £78 060 £61 661 £120 841
Opportunistic (GP)* £70 009 £55 283 £108 578
Opportunistic (MI)† £21 106 £17 116 £32 833
Family tracing £4914‡ £3856 £8 865
*Patients attending general practitioner.
†Patients hospitalised for myocardial infarction.
‡Including cost of finding mutation in proband.
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after treatment. Within each strategy it was more cost
effective to screen younger men and women, although
this trend was less pronounced in women. There was a
10›fold increase in the cost per life year gained
between the oldest and the youngest age group in the
family tracing strategy (table 5). If the genetic mutation
was known within the family then the cost per life year
gained was only slightly increased by genetic diagnos›
tic confirmation (table 5).
Sensitivity analysis
In the analyses we altered the number of first degree
relatives of the proband (which affects the cost
effectiveness of a family tracing strategy—cascade
screening); the proportion of identifiable mutations
(which affects the cost of genetic confirmation of the
diagnosis); drug costs (which are likely to decrease after
the expiry of patents for some statins); attendance
rates; discount rates for cost and effectiveness data; cost
of a coronary event; and life years gained
The ranking of cost effectiveness between or within
the strategies was not affected by any of the sensitivity
analyses (table 6). When we modelled lower drug costs
the cost effectiveness ratio improved most in those
strategies where the drug costs were a larger
proportion of the overall costs. This was particularly
true of the family tracing strategy.
Discussion
This modelling exercise identified screening of
relatives of people with familial hypercholesterolaemia
as the most cost effective way of detecting cases across
the whole population. Familial hypercholesterolaemia
fulfils the World Health Organization criteria for
screening programmes.27 Clinical endpoint trials of
lipid lowering drug treatment with statins have shown
their effectiveness in the primary and secondary
prevention of coronary heart disease risk,7–10 especially
in the groups at highest risk, although there are no
trials specifically in patients with familial hypercholes›
terolaemia. Family tracing in a pilot study in the United
Kingdom was acceptable and feasible,28 and the success
of a programme based on genetic testing in the Neth›
erlands has recently been reported.29 We estimated the
cost effectiveness of family tracing to be £3097 per life
year gained (or £4914 with genetic confirmation). This
represents good value for money compared with
common medical interventions30 and suggests that
pilot evaluation programmes should be conducted.
Screening of patients admitted to hospital with
premature myocardial infarction may be worth consid›
ering but costs three times more per life year gained
compared with family tracing though it ensures
complete coverage. Universal screening restricted to
16 year olds and with clinical methods of diagnosis was
even more cost effective than family tracing. However,
Table 5 Life years gained and cost per life year gained for men and women at different
ages using family tracing strategy with clinical or genetic confirmation of diagnosis
Age›sex group Life years gained discounted at 1% Cost per life year gained
Clinical confirmation (family tracing age 16›54 years)
Men:
16›24 5.0 £870
25›34 2.8 £1468
35›44 0.4 £8278
45›54 0.2 £11 344
Women:
16›24 5.9 £796
25›34 5.6 £766
35›44 5.5 £637
45›54 2.8 £838
All 3.5 £3097
Genetic confirmation (family tracing age 16›54 years, including cost of testing proband)
Men:
16›24 5.0 £1216
25›34 2.8 £2093
35›44 0.4 £12 298
45›54 0.2 £19 591
Women:
16›24 5.9 £1090
25›34 5.6 £1075
35›44 5.5 £953
45›54 2.8 £1470
All 3.5 £4914
Table 6 Effect on estimates of cost effectiveness of changing paramaters used in model (sensitivity analysis)
Universal (at 16 years old) Universal Opportunistic (GP)*
Opportunistic
(MI)† Case finding
Baseline cost per life year gained £2777 £13 029 £11 310 £9281 £3097
Changed assumptions:
1.31 relatives per proband No change No change No change No change £3113
5.75 relatives per proband No change No change No change No change £3092
37% reduction in drug cost £2451 £11 972 £10 352 £6344 £2040
73% reduction in drug cost £2134 £10 944 £9419 £3787 £1011
80% attendance £2651 £12 461 £10 919 £9338 £3102
50% attendance £3499 £17 043 £14 441 £9683 £3128
CHD event cost reduced by 50% £2797 £13 059 £11 338 £9321 £3126
CHD event cost increased by 50% £2757 £13 000 £11 282 £9242 £3067
Life years gained decreased by 50% £5555 £26 058 £22 621 £18 563 £6194
Life years gained increased by 50% £1852 £8686 £7540 £6188 £2065
Genetic
Baseline cost per life year gained £14 842 £78 060 £70 009 £21 106 £4914‡
30% identified mutations £24 142 £128 128 £114 894 £29 670 £5990‡
70% identified mutations £10 856 £56 602 £50 772 £17 448 £4453‡
50% reduction in cost of genetic testing £9753 £50 580 £44 975 £15 682 £4065‡
CHD=coronary heart disease.
*Patients attending general practitioners.
†Patients hospitalised for myocardial infarction.
‡Including cost of testing proband.
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we assumed that 55% of 16 year olds would attend
screening and that most of those diagnosed would
adhere to statin treatment over many years. Neither of
these assumptions can be currently validated and the
ethical acceptability of such a strategy is unclear. Such
a strategy would also, by definition, exclude the
possibility of diagnosis for all those aged over 16 years
and hence its full benefits in reducing population mor›
tality from familial hypercholesterolaemia would not
be seen for many years.
Accuracy of estimates
The estimates of life expectancy of people with familial
hypercholesterolaemia were based on a UK familial
hypercholesterolaemia register.5 11 This may underesti›
mate the true benefit of statins, which have been widely
available for just over 10 years. Earlier identification
and longer treatment are likely to give greater benefit.
On the other hand, the register data may overestimate
the gain in life expectancy because our model used
mortality data before and after the introduction and
widespread use of statins to estimate life years gained
but did not take account of the underlying population
trend of decreasing mortality. In addition, it is possible
that clinics contributing to the register provided closer
medical supervision and more aggressive statin
treatment than elsewhere. As people with familial
hypercholesterolaemia aged over 60 years in the
Simon Broome cohort had a similar mortality and lon›
gevity to the general population neither the costs nor
benefits of treatment were estimated beyond that age.5
Nevertheless, we advocate continuing treatment at this
age.
Awareness by general practitioners, accident and
emergency staff, cardiology teams, and the general
public of the signs of familial hypercholesterolaemia
and the benefits of early treatment is important, and
extra training would be needed. All screening
strategies will become cheaper (and therefore more
cost effective) as drug costs fall, which can be expected
as the patents for some statins expire. The generic
equivalent of a preparation can be between one third
to two thirds of the cost of the proprietary product. As
the technology improves (especially DNA diagnostic
techniques) the cost effectiveness of all strategies will
benefit.
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